New heart failure drug enters first human safety trial
NCT ID NCT07547540
First seen Apr 23, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This early-stage trial will test a single dose of a new drug called LY3971297 in 90 people with two types of heart failure: preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). The main goal is to see if the drug is safe and what side effects occur. Participants will be monitored for about two months, including a 4-day hospital stay and 5 follow-up visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ARENSIA Research Clinic at County Clinical Hospital
Cluj-Napoca, 400347, Romania
Contact
-
ARENSIA Research Clinic at Republican Clinical Hospital
Chisinau, 2025, Moldova
Contact
-
Institut de Cardiologie
Chisinau, 2005, Moldova
Contact
-
Kasumigaura Medical Center
Tsuchiura-shi, 300-8585, Japan
Contact Phone: •••-•••-••••
Contact
-
Kobe University Hospital
Kobe, 650-0017, Japan
Contact Phone: •••-•••-••••
Contact
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
Contact Phone: •••-•••-••••
Contact
-
National Cerebral and Cardiovascular Center
Suita-shi, 564-8565, Japan
Contact Phone: •••-•••-••••
Contact
-
University Medical Center Groningen
Groningen, 9713 GZ, Netherlands
Contact Phone: •••-•••-••••
Contact
-
University of North Carolina, Division of Cardiology
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University
St Louis, Missouri, 63110, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3971297
What this could lead to
If safe, this could pave the way for larger studies testing whether LY3971297 helps control heart failure symptoms.
What could go wrong
This is an early Phase 1 safety trial with only a single dose, so it is not designed to prove effectiveness. Side effects are unknown and the drug may not work in later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.